Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol for Lipoprotein Secretion in Insulin Resistance
NCT01451918Phase 2Completed
- Sponsor
- University Health Network
- Start
- Oct 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia and insulin resistance (IR) comparing Resveratrol with Placebo (2 arms). Primary endpoints: Apolipoprotein B-100 production rate at 2 weeks and Apolipoprotein B-48 production rate at 2 weeks. Started Oct 2011; status: completed.
02
Drugs
resveratrol
03
Conditions
dyslipidemiainsulin resistance (IR)
Beyond the preview
Go deeper on NCT01451918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451918.